Clorox (NYSE:CLX) was downgraded by research analysts at Argus from a “buy” rating to a “hold” rating in a research report issued on Thursday, Marketbeat reports. They presently have a $127.81 price objective on the stock, down from their previous price objective of $150.40. Argus’ price target suggests a potential downside of 0.77% from the company’s previous close.
CLX has been the topic of several other research reports. Deutsche Bank began coverage on Clorox in a research note on Wednesday, December 13th. They issued a “hold” rating and a $142.00 price objective on the stock. BMO Capital Markets set a $147.00 target price on Clorox and gave the company a “buy” rating in a research report on Monday, February 5th. Jefferies Group reaffirmed a “hold” rating and issued a $130.00 target price on shares of Clorox in a research report on Wednesday, December 13th. Bank of America raised Clorox from an “underperform” rating to a “neutral” rating and set a $155.00 target price on the stock in a research report on Thursday, January 4th. Finally, Zacks Investment Research downgraded Clorox from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and four have issued a buy rating to the stock. Clorox has a consensus rating of “Hold” and a consensus price target of $131.97.
Clorox (NYSE:CLX) traded up $1.04 during trading hours on Thursday, reaching $128.80. The company’s stock had a trading volume of 1,720,160 shares, compared to its average volume of 1,347,173. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.35. The company has a market capitalization of $16,667.24, a price-to-earnings ratio of 21.25, a price-to-earnings-growth ratio of 2.41 and a beta of 0.31. Clorox has a 12-month low of $124.09 and a 12-month high of $150.40.
In related news, SVP Michael R. Costello sold 10,574 shares of the stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the sale, the senior vice president now owns 34,867 shares of the company’s stock, valued at $4,742,260.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.00% of the company’s stock.
Large investors have recently modified their holdings of the stock. Phocas Financial Corp. acquired a new stake in Clorox during the second quarter worth approximately $167,000. Dupont Capital Management Corp acquired a new stake in Clorox during the third quarter worth approximately $199,000. Nicholas Hoffman & Company LLC. acquired a new stake in Clorox during the fourth quarter worth approximately $201,000. Smith Moore & CO. acquired a new stake in Clorox during the third quarter worth approximately $204,000. Finally, Private Asset Management Inc. acquired a new stake in Clorox during the fourth quarter worth approximately $208,000. 73.68% of the stock is currently owned by institutional investors and hedge funds.
The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.